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Abstract 
Background: Gambling disorder is prevalent and functionally impairing, yet no FDA approved 
medications exist for its treatment. The ability of clinical trials to discriminate active treatment 
benefits has been hindered by the unusually high placebo response. Virtually nothing is known 
about baseline clinical characteristics that might be predictive of placebo response in gamblers.  
Methods: 152 participants assigned to placebo were pooled from multiple double-blind trials in 
gambling disorder. Participants were classified as placebo responders or non-responders based 
on a cut-off of 35% reduction in symptom severity on the Gambling Severity Scale (GSAS). 
Baseline group differences were characterized using t-tests and equivalent non-parametric tests 
as appropriate.  
Results: Fifty-one percent of individuals assigned to placebo treatment showed a significant 
clinical response to placebo.  Placebo responders stayed in treatment for significantly longer, 
were more likely to endorse ‘enjoyment’ as a trigger for gambling, and were less likely to 
endorse ‘boredom’ or ‘loneliness’ as triggers for gambling. Placebo responders and non-
responders did not differ significantly on age, gender, age at symptom onset, baseline symptom 
severity, comorbidities, or likelihood of having received a previous treatment. 
Conclusions: Predictors of placebo response for gambling disorder appear markedly different 
from those reported for other mental health disorders.  
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Introduction 
Gambling disorder is a potentially disabling global mental health problem in which 
individuals develop a maladaptive form of gambling behavior associated with impaired 
functioning, reduced quality of life, and high rates of bankruptcy and divorce (1).  Many 
individuals with gambling disorder report intrusive thoughts and urges related to gambling that 
interfere with their ability to concentrate at home and at work, and work-related problems such 
as absenteeism and poor performance are common (2). Gambling disorder is also frequently 
associated with marital problems, diminished intimacy and trust within the family, as well as 
greater rates of health problems (e.g., hypertension, obesity, insomnia) (3-4). Thus, effective 
treatments for gambling disorder are needed.  
After approximately three decades of pharmacological research, there are no Food and 
Drug Administration (FDA)-approved treatments for gambling disorder. Many of the double-
blind, placebo-controlled pharmacological studies of this disorder have failed to separate from 
placebo. Interestingly, this has often been due to very high rates of placebo responders (i.e. 47% 
to 72%) (5-7). Understanding the complexity of the placebo response in gambling disorder has 
been challenging due to the limited sizes of the research samples. The present study seeks to 
overcome this limitation by using a relatively large data set, which combines participants from 
eight double-blind, placebo controlled pharmacological trials in gambling disorder (8-15). 
As it is generally understood, a placebo is an inert substance with no direct peripheral or 
central nervous system effects. There is often a strong response to a placebo, however, and this 
may be due to multiple factors. Some research suggests that the placebo effect in clinical drug 
trials generally may influence as many as 49% of treated patients, that the effect may be 
unrelated to symptom severity, and that its duration may vary from minutes to years (16).  The 
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placebo effect also appears to vary in strength based on different indications and what is being 
measured (for example, subjective versus objective endpoints) (17), and may further be 
influenced by factors such as genetics, patient expectations, and even the color and size of the 
placebo (18-21). In fact, there may be multiple placebo effects, or multiple mediators of the 
placebo effect, not simply a single factor contributing to this phenomenon (22-23).  
Understanding the factors associated with the placebo effect in gambling disorder may 
allow for a more efficient examination of potentially beneficial pharmacological treatments for 
this disabling disorder.  Here, we pooled data from studies conducted by the same group of 
researchers, in which all participants met diagnostic criteria for gambling disorder, took placebo-
pills, and were seen regularly by a medical professional. Unlike studies of alcohol use disorders 
which involved combination treatments with therapy and therefore may have complicated the 
understanding of a placebo response (24-25), these studies were all comparative studies of 
medication versus placebo, in the absence of potentially confounding effects of concomitant 
psychotherapy. Based on the extant mental health literature, we hypothesized that the placebo 
effect in gambling disorder would be associated with younger age, shorter duration of illness, 
milder gambling illness severity at baseline, plus milder anxiety and depressive symptoms at 
baseline (26-30).   
 
Methods 
Subjects 
Data from participants in gambling disorder treatment studies at the University of 
Chicago and the University of Minnesota, who were assigned to placebo during the clinical trial, 
were included in this study. A diagnosis of gambling disorder was confirmed by the primary 
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investigator, a board-certified psychiatrist, using the criteria set forth by the DSM-IV (31) and 
the diagnoses were later confirmed to be consistent with the current requirements for gambling 
disorder using the DSM-5 criteria (32). Exclusion criteria for these studies included current 
illegal drug use, any history of psychotic or bipolar disorder, any current psychotherapy, or 
inability to provide informed consent.  
Data from eight, double-blind, placebo-controlled published trials were included (8-15). 
Of the eight studies, two examined naltrexone, two studied nalmefene, two focused on N-acetyl 
cysteine, and two involved paroxetine. Measures common to all studies included those analyzed 
in this study (see below). The studies differed in length with a range from 8 to 16 weeks.   
All study procedures were carried out in accordance with the Declaration of Helsinki. 
The Institutional Review Boards of the University of Minnesota and of the University of Chicago 
approved the procedures and the accompanying consent forms. After all procedures were 
explained, all subjects provided informed written consent. 
After providing informed consent, all participants in the trials completed a full 
psychiatric assessment using the Structured Clinical Interview for DSM-IV (SCID-I) (33). 
Subjects also completed general demographic questionnaires, self-report and clinician-
administered severity measures, as well as information about symptom triggers.    
 
Assessments 
All participants underwent a semi-structured interview assessing gambling behavior: age 
at onset of gambling and problems due to gambling. In addition, all participants completed the 
following measures: 
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Gambling symptoms during the past 12 months were evaluated using the Structured 
Clinical Interview for Gambling Disorder (SCI-GD), a nine-item instrument covering the DSM-5 
criteria (31; modified to reflect DSM-5).  
Yale-Brown Obsessive-Compulsive Scale modified for Pathological Gambling (PG-
YBOCS): The PG-YBOCS is a clinician-administered scale that assesses severity of urges and 
behaviors related to gambling during the past week, with higher scores indicating greater severity 
(34).  
Gambling Symptom Assessment Scale (GSAS): The GSAS is a reliable self-report 
measure that assesses gambling symptom severity over the last week. Scores are based on ten 
questions, with each being scored from 0-4, with a maximum possible severity score of 40. The 
scale covers a range of symptoms related to gambling disorder, including the severity, duration, 
and frequency of both urges and behaviors related to gambling (35). 
Hamilton Depression Rating Scale (HAM-D): The HAM-D is a clinician-administered 
scale which assesses a patient’s level of depression during the past month (36).  
Hamilton Anxiety Rating Scale (HAM-A): The HAM-A is a clinician-administered scale 
which assesses a patient’s level of anxiety during the past month (37). 
Sheehan Disability Scale (SDS): The Sheehan Disability Scale is a valid and reliable, 
three-item, self-report scale that assesses psychosocial functioning in work, social or leisure 
activities, and home/family life (38). 
 
Data Analysis 
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Baseline characteristics of the placebo participants pooled from all of the studies were 
presented in terms of means and standard deviations for continuous variables and frequencies 
and percentages for categorical variables.  
Patients were grouped as placebo responders (>35% reduction in GSAS total scores from 
baseline to end-point) or non-responders. The two groups were compared on pertinent 
demographic, clinical, and cognitive measures using independent sample t-tests or equivalent 
non-parametric tests as indicated in the text. This being an exploratory study, statistical 
significance was defined as p<0.05 uncorrected, two-tailed. 
 
Results 
  Data from 152 participants with primary gambling disorder (N=63 [41.5%] female, mean 
age 45.9 ± 11.9 years) who were assigned placebo were included in the analysis. In the pooled 
analysis, 51.3% of participants assigned to placebo improved at least 35% on GSAS during 
placebo treatment.  
Clinical variables of responders and non-responders are presented in Table 1, where it 
can be seen that the groups did not differ from each other in terms of age, gender, or educational 
level. The responder group had a significantly lower proportion of participants with White 
Caucasian ethnicity versus the other group.  
 The placebo responders group, compared to the non-responders group, showed 
significantly more weeks of study  completion, were more likely to endorse ‘enjoyment’ as a 
trigger for gambling, and were less likely to endorse ‘feeling sad’ or ‘loneliness’ as triggers for 
gambling. State mood and anxiety, history of comorbid mental disorders, and previous treatment 
status did not significantly differ between the two groups.  
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Table 1. Clinical Variables of Participants with Gambling Disorder Who Did and Did Not 
Respond to Placebo 
Variables Those Who 
Responded to 
Placebo (n=78) 
Those Who Did 
Not Respond to 
Placebo (n=74) 
Statistical Test P 
value 
Age, years 
46.4 (10.4) 
45.5 (13.4) t-test=-0.476 
df=150 
0.635 
Gender, female, N [%] 
31 [39.7%] 
32 [43.2%] LR chi-square = 0.192 0.662 
Education level 
2.8 (1.1) 
3.3 (1.1) t-test=1.705 
df=78 
0.092 
Race, white Caucasian, N 
[%] 58 [74.4%] 
65 [87.8%] LR chi-square = 4.572 0.033 
Age at onset of gambling  
23.0 (12.2) 
 
25.3 (11.9) 
t-test=1.121 
df=135 
.264 
G-SAS baseline score 36.3 (9.6) 33.6 (9.0) t-test=-1.723 
df=149 
.087 
PG-YBOCS 
Urge subscale 
Behavior subscale 
Total score 
 
11.3 (2.7) 
12.1 (2.8) 
23.4 (4.8) 
 
11.4 (2.6) 
11.9 (3.20 
23.3 (5.2) 
 
t-test=0.235; df=125 
t-test=-0.387; df=125 
t-test=-0.107; df=125 
 
.815 
.699 
.915 
Weeks of study completed 
13.2 (4.2) 
 
10.6 (5.1) 
t-test=-3.379 
df=150 
<.001 
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Previous treatment for 
gambling, yes, N[%] 
29 [42.7%] 
26 [46.4%] LR chi-square = 0.178 0.673 
Triggers to gambling, n {%] 
Enjoyment 
Having money 
Depression 
Feeling sad 
Loneliness 
Boredom 
 
4 [19.1%] 
12 [84.0%] 
4 [16.0%] 
0 [0%] 
2 [8.0%] 
10 [40.0%] 
 
0 [0%] 
12 [42.9%] 
8 [28.9%] 
3 [10.7%] 
10 [35.7%] 
6 [21.4%] 
 
LR Chi-square = 6.380 
LR Chi-square = 0.141 
LR Chi-square = 1.214 
LR Chi-square = 3.989 
LR Chi-square = 6.263 
LR Chi-square = 2.173 
 
0.012 
0.707 
0.271 
0.046 
0.012 
0.140 
Sheehan Disability Scale 
17.1 (6.1) 
16.7 (6.7) t-test=-0.358 
df=114 
.721 
HAMA 
6.39 (4.35) 
8.01 (5.13) t-test=1.509 
df=78 
.135 
HAMD 
6.39 (3.96) 
7.56 (4.99) t-test=1.145 
df=78 
.256 
Lifetime Psychiatric 
Comorbidity 
Mood Disorder 
Anxiety Disorder 
Alcohol Use Disorder 
Behavioral Addiction 
 
 
16 [23.5%] 
5 [7.4%] 
8 [11.8%] 
2 [5.4%] 
 
15 [26.8%] 
5 [8.9%] 
8 [14.3%] 
7 [15.9%] 
 
LR Chi-square = 0.173 
LR Chi-square = 0.102 
LR Chi-square = 0.173 
LR Chi-square = 2.392 
 
0.677 
0.749 
0.678 
0.122 
All values are mean (±SD) for continuous variables and N [%] for categorical variables. LR = 
likelihood ratio test. 
 
Discussion 
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 This is the first study we are aware of that examines clinical variables associated with the 
placebo response in the pharmacological treatment of gambling disorder. Given that the pooled 
placebo response in these studies was 51%, and that there is as of yet no FDA-approved 
medication, determining predictors of placebo response is crucial for the timely and cost-
effective development of pharmacological interventions.  Knowledge of variables associated 
with placebo response might also be useful for sample enrichment in clinical trials.  
 This study found that those who completed more weeks of treatment, those who endorsed  
 ‘enjoyment’ as a trigger for gambling, and those who did not endorse ‘feeling sad’ or 
‘loneliness’ as triggers for gambling, were more likely to be placebo responders. Contrary to our 
expectations, baseline symptom severity, gambling at a younger age, and previous treatment for 
gambling disorder did not differ between placebo responders and non-responders. The 
differences between our results and studies of other mental health conditions in which younger 
age and previous treatment were meaningful predictors of placebo response (28, 30, 39-40) could 
reflect the particular characteristics of our subject population or of the disorder itself.  
 Given the relative paucity of side effects associated with placebo, and the high rate of 
response to placebo observed in this pooled dataset, these findings raise the crucial question of 
whether placebo should be used for the treatment of gambling disorder.  The ethical implications 
of this option have been debated for decades (41). In the case of gambling disorder, we know 
that in one of the studies, the placebo response was robust for the entire 4-month period of the 
study (10). Therefore, the placebo effect may not be transient for gambling disorder as it is for 
other health conditions (42). The current findings add another layer to the debate about the 
possible use of placebos in clinic settings. 
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 This study suggests that few baseline clinical characteristics in gambling disorder 
distinguish placebo responders from non-responders, but there exist several limitations to the 
studies included in the pooled analysis. First, some data suggest that expectancy (i.e. an 
individual’s beliefs about whether he or she will improve due to the treatment) may play a large 
role in a placebo response (41, 43). Expectancy was not measured in the studies analyzed here. 
Second, although the G-SAS scoring has demonstrated strong validity and reliability in previous 
trials as reflecting a response to medication (35), the ideal assessment of (and threshold for) 
gambling disorder response remains somewhat in doubt (44). Third, some clinical measures were 
available only for a subset of individuals in the pooled dataset (e.g., rates of behavioral 
addictions were not examined in the earlier studies). Fourth, the finding that placebo responders 
were more able to experience pleasure as a trigger and less likely to report sadness raises the 
question as to whether the affective state at the time of testing would affect the placebo response. 
Unfortunately this was no examined in these studied. Finally, this study did not examine baseline 
brain function (e.g. cognition, blood oxygen level dependent activation) that might be predictive 
of placebo response, nor such changes over the course of placebo treatment. This may in the 
future be a useful means of distinguishing placebo responders from non-responders before 
treatment, especially given that the placebo response can be linked with neural changes (45).  
 Placebo controlled studies are the gold standard for the examination of pharmacological 
interventions. Individuals with gambling disorder who respond to placebo appear to have 
different distributions of triggers for their gambling behavior – being disproportionately more 
likely to endorse enjoyment as a gambling trigger, and less likely to endorse feeling sad/lonely as 
a trigger. Furthermore, placebo responders may potentially benefit from longer interventions 
than non-responders. Given the global health problems associated with gambling disorder (1), 
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understanding the  placebo response will be crucial for developing better pharmacological 
interventions for  this disorder. Since opioid and dopamine pathways are implicated both in 
gambling disorder and in the placebo response (29, 46-47), gambling disorder may be a 
particularly fruitful condition with which to study the neurobiological basis of placebo response.   
In addition, this study suggests that those who were in the studies longer had a stronger placebo 
response, but we have no clear data regarding how long the placebo effect lasts. Future studies 
therefore may also wish to focus on several unanswered questions such as the duration of the 
placebo effect in gambling disorder, whether incentives that increase the time spent in the study 
increase the placebo response, and whether short studies of say two to four weeks may decrease 
the placebo effect and be more fruitful in finding beneficial pharmacological treatments for 
gambling disorder.   
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